Dannemann Siemsen Institute promotes debate on the manufacture of compounded medications based on third-party patents and their legal, regulatory, and health impacts.
On July 28, the Dannemann Siemsen Institute (IDS) hosted another edition of Agenda IDS, featuring an in-depth debate on the indiscriminate manufacturing and use of compounded medications involving...
read +